Replay available

Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2022 Earnings Call

Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2022 earnings call, held 2022-05-11. Watch the replay and read the transcript on 6ix.

Wed, May 11, 2022 at 8:30 AMendedReplay
Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2022 Earnings Call
Company
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)
Period
Q1 2022 earnings call
Date
Wed, May 11, 2022, 8:30 AM ET
Replay
Watch the replay on this page · 22 min
Results news release
Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update · Wed, May 11, 2022

On 6ix: 6ix.com/event/acurx-pharmaceuticals-inc-acxp-q1-2022-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Greetings and welcome to the AccuS Pharmaceuticals, Inc. first quarter 2022 results and business updates. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. If anyone should require an operator during the conference, click the star and then zero on your keypad. As a reminder, the conference is being recorded. I would now like to turn the conference over to your host, Robert Shawah, Chief Financial Officer. Please go ahead.

0:35 Thank you. Good morning and welcome to our call. This morning we issued a press release providing financial results and company highlights for the first quarter of 2022. This press release is available on our website at acrexpharmaceuticals.com. Joining me today is Dave Lucci, President and CEO of Acrex, will give a corporate update and outlook for the remainder of 2022. After that, I'll provide some highlights of the financials from the quarter ended March 31, and then turn the call back over to Dave for his closing remarks. As a reminder, during today's call, we'll be making certain forward-looking statements. These forward-looking statements are based on current information, assumptions, estimates, and projections about future events that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.

1:31 Investors should consider these risks and other information described in our filings made with the Securities and Exchange Commission, including our quarterly report on Form 10-Q, which we filed yesterday, Tuesday, May 10th. You are cautioned not to place undue reliance on these forward-looking statements, and ACREX disclaims any obligation to update such statements at any time in the future. This conference call contains time-sensitive information that's accurate only as of the date of this live broadcast today, May 11th. Accrax undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date and time of this conference call. I'll now turn the call over to Dave Lucci. Dave?

2:15 Thanks, Rob. Good morning, everyone, and thanks for joining us on this conference call to review our financial results. During today's call, we'll review our financial results for the first quarter ended March 31, and also cover some key corporate highlights, and then we'd be pleased to take any questions. In the first quarter, more patients were enrolled in the Phase 2B clinical trial of Ibezapulset, our lead antibiotic candidate, for the treatment of patients with C. difficile infection, or CDI. The Phase 2B clinical trial is a 64-patient, randomized one-to-one, non-inferiority, double-blind trial of oral ibuprofen compared to oral vancomycin, a standard of care to treat CDI.

3:02 The primary endpoint of the Phase IIb trial is clinical cure of the C. difficile infection at the end of treatment measured on Day 12, and a secondary endpoint is sustained clinical cure measured at Day 38 follow-up visit. Since this is a double-blind trial, results will not be known until the end of the trial. However, operationally, the trial is proceeding as expected, signals reported to date. Also included in the protocol is an exploratory endpoint comparing the impact on the microbiome between ibezopolstat and vancomycin. In the event non-inferiority of ibezopolstat to vancomycin is demonstrated in the Phase IIb trial, further analysis will be conducted to test for superiority.

3:51 Additionally, based on the strength of our previously reported Phase IIa results, which demonstrated 100% clinical cure in patients after a 10-day treatment for CDI with no recurrences of infection at the day 38 follow-up visit, we've added a novel exploratory endpoint in the Phase IIb trial of extended clinical cure, or ECC, for study visits at day 56 and day 84 after the end of treatment for a selected group of subjects to evaluate the longer-term effect of ibuprofen on the microbiome and on disease recurrence. To our knowledge, no other comparable long-term data such as this has been conducted or reported with currently used antibiotics to treat C. difficile infection to date.

4:43 The Phase 2B clinical trial will include up to 24 U.S. sites with enrollment expected to be completed late in the second half of this year. We remain particularly excited about the dual impact of using Ivesipulstat to treat the acute infection, CDI, while appropriately managing the long-term care of each patient's microbiome, which we believe is exceptional for antibiotic therapy. We reiterate that with the closing of our IPO in June 2021, we have more than enough cash to complete the Ibezapolstat Phase 2b trial and related R&D matters, as well as to allocate resource to advance development of ACX375C, our second DNA Pol3C inhibitor, currently in lead optimization stage of preclinical development for the treatment of other gram-positive bacterial infections, including MRSA.

5:42 Other key highlights from the first quarter of 22 include the following. Our laboratory study at the University of Houston comparing microbiome changes of Ibezopulstat to vancomycin, fidaxamycin, and metronidazole using both in vitro and ex vivo analyses is ongoing. The objective of this study is to expand our very positive Phase I and Phase IIa microbiome data using an in vitro gut model that mimics human gastrointestinal physiology. Shortly after the end of the first quarter, we submitted a grant application to the NIH National Institute of Allergy and Infectious Disease for approximately $23 million of non-diluted funding to support the ongoing development of ACX375C.

6:32 If approved, these funds would cover the costs of ACX375C all the way through phase one clinical trials for our lead clinical indication including reimbursement to the company for certain GNA costs. The company anticipates a final decision on this funding opportunity in the second half of this year and we will continue to monitor other potential funding opportunities and we do anticipate submitting at least one more application in this regard for external funding this year. We're continuing our scientific collaboration with Leiden University Medical Center to further study the mechanism of action of PAL3C inhibitors in a consortium partnership with our company. The innovative research project under a $500 million grant to the Leiden University Medical Center with Acurex as its consortium partner is studying three-dimensional structures of DNA polymerases.

7:33 and their binding interaction with Acorex inhibitors. The antibacterial molecular target of Acorex's pipeline of novel DNA Pol3C inhibitors has been clinically validated by Avesa Polestat's recent completion of its Phase 2A trial in CDI. The research outcome at Leiden University Medical Center is intended to accelerate lead product candidate selection for our ACX375C program for systemic treatment against multidrug-resistant gram-positive bacteria where new classes of antibiotics are urgently needed. This project was initiated by Leiden University Medical Center in September 2021, and emerging data are expected to facilitate the 375 program.

8:24 Now I'll turn the call back to our CFO, Rob Shaila, to guide you through the highlights of our financial results for the first quarter of 22. Rob?

8:34 Thanks, Dave. Our financial results for the first quarter ended March 31, 2022 were included in our press release issued earlier this morning. Acurex ended the first quarter on March 31 with cash totaling $11.1 million compared to $13 million as of December 31, 2021. Cash used in operating activities for the quarter ended March 31 was $1.9 million of which approximately .5 million dollars was spent on research and development related activities. Research and development expenses for the quarter ended March 31 were .8 million dollars compared to .1 million dollars for the quarter ended March 31, 2021.

9:21 The increase is due primarily to Phase 2B trial related costs and increase in consulting costs. General administrative expenses for the quarter ended March 31 were 1.9 million dollars compared to $1.4 million for the quarter ended March 31, 2021. The increase was primarily due to increases in professional fees, legal and insurance costs. The company reported a net loss of $2.7 million or 26 cents per diluted share for the three months ended March 31, 2022 compared to a net loss of $1.5 million were 21 cents per diluted share for the three months ended March 31, 2021.

10:06 The company had 10,263,202 shares outstanding as of March 31, 2022. With that, I'll turn the call back over to Dave.

10:21 Thanks, Rob. And thank you all for joining us today. We're very enthusiastic about the strong fundamentals of our company. and we're especially pleased to report Acorex's continuing progress in the first quarter of 22. We look forward to building on this momentum this year and to updating you in the coming months. I'll now open up the call for questions. Operator? Thank you, sir. Ladies and gentlemen, at this point, we will be conducting a question and answer session. If you would like to ask a question, please press star and then one on your telephone key card. A confirmation tone will indicate your line is in the question queue. You may press star and then two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star key. The first question we have is from Chad Yan from Maximum Group. Please go ahead.

11:22 Hi, guys. Congrats on the quarter. Other than Ibizepolsat, are there any other competing antibiotics in the space as advanced, particularly given the setbacks Summit has had?

11:38 Well, thank you for your question. Now, there are no other antibiotics that are anywhere near as far along as we are in the R&D development phase to treat CDI. There is a product that's much earlier on than where we are in a private company called Crestone that we're aware of. But we understand they don't have any efficacy data yet. So there's no telling. They're much earlier on than we are. And we do also note that Pfizer recently announced that their attempt at a vaccine failed the Phase 3 primary endpoint test. and they're parsing the data and looking to be just a kind of a niche player toward the back end in a subgroup of C. diff patients, but no longer targeting frontline.

12:34 So really, you know, the C's have kind of parted for us, you know, as Summit's program had failed phase three and the Pfizer vaccine, you know, failed, the primary endpoint is no longer considered a frontline candidate. and Sanofi back in 2017 also tried a vaccine to treat C. diff patients and that failed as well.

13:01 Great, great. Thanks there. And then also, any updates on the progress with the Pasteur Act?

13:10 The Pasteur Act is, it's very close and we understand through our affiliation with the Antimicrobial Working Group and the BioIndustry Organization that it was part of an omnibus bill that was recently approved, I think back in March, and it got scratched in the ninth inning late in the game, replaced by a national defense appropriation in its stead. And that was back shortly after the war between Russia and Ukraine kind of hit the news. So most folks in the industry believe that the Pastorets will be approved as part of other legislation at some point later this year.

14:05 And we do know in that regard that the bill has bipartisan support, including Nancy Pelosi and Patty Murray on the Democrat side, along with several Republicans, some of whom are sponsoring the bill. So that's all we know for now, but certainly the passage of the Pasteur Act would kind of really be tremendously beneficial for any incubator company with a new class of antibiotics that's QIDP like ours, treating serious and life-threatening infections.

14:45 Great, thanks. And then just one last one. Could you talk about the pipeline and the next, the POL3C inhibitor? And also, I guess, what do you think in your view would be the potential of having intravenous as well as oral, and is that a strategy you could pursue?

15:06 Thanks. Yes, and in fact, we are pursuing that strategy with ACX375C. which is the next drug in the pipeline. We are at the lead optimization stage of preclinical development with 375C. You know, we can say that the lead optimization process is really picking up steam and we expect in the second half to be lead optimized and to be then going into IND enabling preclin tox work. And yes, We expect 375C to be oral and IV. We're working on both. And that's new because ACX375C, as we've discussed before, is very close to Cubicin in terms of the bacteria it's able to kill.

16:05 Very similar minimum inhibitory concentration data between the two programs. Now, Cubicin was a blockbuster drug, but it was only IV. And we target the same bacteria, so we should be used for the same infections if the trials go well. But ours is oral and IV. So, if anything, it should be a bigger drug than Cubicin, subject, of course, to having to get through the R&D gauntlet.

16:40 Great, thanks so much.

16:43 Thank you. Ladies and gentlemen, just a reminder, if you would like to ask a question, please press star and then one, no. The next question we have is from Jason McCarthy of Maxine Group.

17:00 Hi, this is Joanne Lee on the call for Jason McCarthy. Thanks for taking the question. Regarding your IBEZA Pulse App program, could you just shed some color and maybe What would be the size and scope of a Phase 3 program should the Phase 2B be successful?

17:16 Thank you, Joanne. Thank you for the question. So it's a bit early to understand exactly what the size and scope of Phase 3 would be. Until we get to make that determination, we have to finish the 2B trial and assess the data. and then meet with the FDA with our going in strategy. It's possible that as a qualified infectious disease product and fast track designated product and subject to what other programs are doing or have done like Summit, it's possible that we may be able to do just one phase three trial or we may be able to do or we may have to do two phase three trials.

18:04 Overall, we would guess, and this is very speculative, but the Phase 3 patient mandate, whether it's in one or two trials as a setting, would be somewhere in the 400 to 500 patient range.

18:22 Great. That was helpful. Appreciate the details. So with current guidelines for CDI management, could you just share your thoughts on if the next drug is approved, will vancomycin be used anymore? What does that mean for a drug like abezapolstat moving into frontline therapy?

18:38 Thanks. Sure. No problem. As we understand it, from those who draft the Infectious Disease Society of America treatment guidelines to treat CDI, with the advent of the next antibiotic or other therapy that's FDA-approved to treat CDI, vancomycin very likely will be removed from the IDFA guidelines recommendation list, much like metronidazole was removed a couple of years ago. And that's because, and it's an indication that vancomycin, even a world vancomycin, is a very vulnerable frontline therapy.

19:24 And we think that's why folks like Pfizer and Sanofi and Summit selected CDI as a clinical target because they knew that if they were to get through and become frontline therapy in a $1.7 billion market, they would have potentially a blockbuster.

19:45 Great. Thank you for that. And last one for me. Can you talk about big pharma interest in CDI, particularly Pfizer? I know you touched on this briefly earlier, but do you see them coming back to infectious disease more today than before? and how does Acurex think about potential partnering opportunities?

20:05 We think, we think, I think about potential partnering opportunities every day. And, you know, we don't know, you know, who will come out when. We have ongoing discussions. You know, if you read the Fierce Biotech article after Pfizer announced that It's bid for frontline therapy for CDI with the vaccine failed. Pfizer indicated that their intent to remain in the CDI space as a niche product in multiple recurrent cases, and obviously they'll have to do additional work in order to get even that, but they fully acknowledge that their bid for frontline therapy is over, but they want to stay in the space because they see the value of the space given There's so little out there that's effective. So, yeah, we have active discussions ongoing with Big Pharma, and we're not sure where that's all going to go, whether that will lead to a deal. And if it leads to a deal, we're not sure if that would be a deal before the data or after the data.

21:18 Got it. Makes sense. Appreciate your insights, David. Thanks again for taking the questions.

21:22 No problem. We appreciate it. Ladies and gentlemen, just a final reminder, if you would like to ask a question, please press star and then one now. We'll pause a moment to see if we have any further questions. At this stage, there are no further questions. Ladies and gentlemen, That concludes today's question and answer session and the conference call. Thank you for your participation. You may now disconnect your lines.

22:07 Thank you.

Follow Acurx Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Dave Lucci

President and CEO

Chad Yan

Analyst, Maximum Group

Robert Shawah

Chief Financial Officer

Joanne Lee

Analyst, Maximum Group (for Jason McCarthy)

More from Acurx Pharmaceuticals, Inc.